Indirect Treatment Comparisons and Payer Implications in Adjunctive MDD Therapy

With no head-to-head trials among the five adjunctive antipsychotics approved for major depressive disorder, payers default to skepticism toward branded options unless indirect comparative evidence proves added value beyond cost.

Before comparing therapies, clinicians need the statistical vocabulary: what a p-value actually measures, why effect size matters more, and how network meta-analysis links trials through a shared placebo comparison.

The study's own senior author walks through its design, then reveals meaningful differences in weight gain, akathisia, and sedation risk that should inform how clinicians and payers evaluate these agents.

An independently conducted meta-analysis confirms similar efficacy but surfaces a notable acceptability gap, underscoring why shared decision-making and patient preference remain central to prescribing.

Looking ahead, Dr. Citrome weighs how payers should structure formulary access today against the long-term evidence still missing on treatment duration and relapse risk.